Related Experiment Video
Updated: Dec 23, 2025
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Toxicity outcome of endorectal brachytherapy boost in medically inoperable patients
C L Chiang1,2,3, S F Lee4, Venus Wy Lee4
1Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, China. chiangcl@hku.hk.
Aim:
This communication reviews results and toxicity of image-guided high-dose-rate endorectal brachytherapy (HDREBT) boost after external beam radiotherapy (ERT) in medically inoperable patients with rectal cancer.
Materials And Methods:
A total of 18 patients with rectal cancer and clinical stage T2-4N0‑2 treated with HDREBT boost after ERT were retrospectively reviewed.
Results:
Following treatment with a median total dose (EQD2, α/β = 10) of 66 Gy (range 48-92 Gy), the incidence of early and late rectal grade 3 toxicity was 11% and 19%, respectively. There was no correlation between the occurrence of acute and late toxicity.
Conclusion:
With proper technique, a combined approach using EBRT and HDREBT was associated with acceptable toxicity in medically inoperable rectal cancer patients.
